The anti-migraine properties of triptans may be due to vasoconstriction of the carotid arterial bed via 5-HT1B receptors and the inhibition of CGRP release from trigeminal nerves via 5-HT1B/D receptors, in our study sumatriptan forms were inactive in the capsaicin test. This evidence concerns the gene HTR1B and migraine disorder.